Asthma Clinical Trial
Official title:
Does Improved Information in the Form of Group Discussions With Parents of Newly Diagnosed Asth-Matic Children Lead to a Better Quality of Life for the Families, an Improved Adherence and Better Devel-Opment of the Lung Function of the Children?
We wanted to investigate if it was possible to improve adherence to prescriptions and advice in pre-school children with newly diagnosed asthma. The intervention was intense information and support in the form of four group discussions with the parents of four children in close connection to diagnosing the child. The control children received the usual care with individual polyclinic visits to the physi-cian/nurse. We evaluated the effect with the help of questionnaires, physical examinations, blood tests, lung function tests and control of treatment adherence after 18 months and 6 years.
Poor adherence to the prescribed regimen of medication is one of the major obstacles to
successful treatment of many chronic diseases, in the case of both grown-ups and children.
In 1998 we initiated a randomized, prospective intervention study with per protocol design
involving 60 young children re-cently diagnosed as having asthma and with a high risk that
this condition would persist.
The parents of the children in the intervention group received extra support and information
in the form of group discussions, whereas the control patients were treated in a routine
manner. All children 0-6 years of age who fulfilled at least one of the criteria for risk of
persistent asthma among the 9410 children in our catchments area were evaluated at our
out-patient clinic during a period of 1.5 years beginning in 1998. Of the 66 patients thus
identified the parents of 6 declined to participate and the remaining 60 children were
randomized consecutively in groups of four by a nurse to either the inter-vention or the
control group. The groups turned out to be well-matched.
All of the children received the usual management and care, including individual oral and
written information concerning how to deal with their asthma. The intervention consisted of
additional infor-mation and support in a group setting, with three 1.5-hour meetings soon
after inclusion in the study (with 70% participation, no gender difference) and a fourth
meeting 6 months later (with 40% partici-pation). The three nurses, three pediatricians and
two psychologists who performed this investigation were also in charge of the intervention,
i.e. the study was not blinded.
The initial examination included a clinical examination, spirometry, chest x-ray,
examination of the patients' records and questionnaires concerning issues of adherence,
burden of asthma and quality of life (Pediatric Caregiver's Quality of Life Questionnaire,
PACQLQ). This Questionnaire was filled out separately by the fathers and the mothers and a
change of > 0.5 units on a 7-point scale was considered to be clinically important. The
blood and urine were analyzed for inflammatory parameters. Skin prick tests were performed
being considered positive if the mean diameter of the wheal was >3 mm. The al-lergen
extracts used were Soluprick® (ALK-Albello A/S, Denmark) and included egg, birch, timothy,
mugwort, dog, cat, horse and Dermatophagoides pteronyssinus. RAST® testing (Pharmacia
Diagnos-tics & Upjohn AB) with the same allergens (considered positive when the IgE-level
was >0.7 kU/l) and Phadiatop® testing (Pharmacia Diagnostics & Upjohn AB) (considered
positive if the value > 1.0 kU/l) were also performed.
The children made regular visits to their own pediatrician and nurse during the subsequent
years and their medical records have been continuously updated and computerized. The
examination after 6 years was performed during 2005. In this context each child was examined
and interviewed, in the company of one or both parents and the examination being the same as
earlier, except that no chest x-ray or objective assessment of adherence was carried out.
This time separate questionnaires addressed to the child (the Pediatric Asthma Quality of
Life Questionnaire) and to the child and parent together (the Asthma Control Questionnaire)
were included, with a value of < 0.75 considered as being an indicator of good asthma
control. Furthermore exhaled NO was measured with the help of the NIOXMINO® Airway
Inflammation Monitor (Aerocrine AB, Solna, Sweden), utilizing a 10-sec expiration at a
constant flow rate of 0.05 l/s. In addition, we per-formed dry-air tests (Aiolos AB,
Karlstad, Sweden), in connection with which a fall in FEV1 of > 10% was considered
pathological.
During the follow-up parents and doctors estimated adherence on a visual analogue scale
(VAS). The children were told to begin taking high doses of ICS (0.2 mgx4) as soon as they
caught a cold, even before they had any asthmatic symptoms, and to subsequently reduce the
dose gradually during the first week, stopping medication when they no longer had any
symptoms. When symptoms of asthma developed they were instructed to continue ICS for one
month and, if they had experienced three or more exacerbations during a12-month period, to
continue this treatment for another six months.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|